ASCENDIS PHARMA A/S's ticker is ASND and the CUSIP is 04351P101. A total of 168 filers reported holding ASCENDIS PHARMA A/S in Q1 2023. The put-call ratio across all filers is 0.19 and the average weighting 0.6%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $319,593 | +9423.0% | 3,413 | -87.6% | 0.00% | -95.5% |
| Q4 2022 | $3,356 | -99.9% | 27,476 | -14.0% | 0.07% | -7.0% |
| Q3 2022 | $3,297,000 | +70.4% | 31,932 | +53.4% | 0.07% | +39.2% |
| Q2 2022 | $1,935,000 | +72.9% | 20,814 | +144.6% | 0.05% | +142.9% |
| Q2 2021 | $1,119,000 | -54.0% | 8,509 | -54.9% | 0.02% | -57.1% |
| Q1 2021 | $2,431,000 | +13.2% | 18,862 | +46.5% | 0.05% | -19.7% |
| Q4 2020 | $2,147,000 | +196.1% | 12,872 | +173.9% | 0.06% | +90.6% |
| Q3 2020 | $725,000 | +56.9% | 4,700 | +50.4% | 0.03% | +39.1% |
| Q2 2020 | $462,000 | -39.7% | 3,125 | -73.3% | 0.02% | -8.0% |
| Q1 2018 | $766,000 | +154.5% | 11,705 | +55.9% | 0.02% | +212.5% |
| Q4 2017 | $301,000 | +40.0% | 7,510 | +26.9% | 0.01% | +60.0% |
| Q3 2017 | $215,000 | – | 5,918 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Vivo Capital, LLC | 1,797,745 | $265,886,000 | 19.06% |
| RA Capital Management | 4,914,955 | $726,922,000 | 14.16% |
| Sofinnova Investments, Inc. | 1,109,874 | $164,150,000 | 10.35% |
| Eventide Asset Management | 1,709,848 | $252,887,000 | 5.50% |
| Asymmetry Capital Management, L.P. | 47,599 | $7,040,000 | 5.39% |
| BERYLSON CAPITAL PARTNERS, LLC | 58,200 | $8,608,000 | 5.30% |
| Avoro Capital Advisors LLC | 1,750,000 | $258,825,000 | 5.12% |
| Eversept Partners, LP | 220,344 | $32,588,878 | 4.47% |
| Spyglass Capital Management LLC | 452,104 | $66,866,000 | 4.14% |
| Orbimed Advisors | 1,562,986 | $231,166,000 | 3.25% |